Insurance coverage, out-of-pocket costs, benefits, billing, and access-related changes.
The short answer is not yet. Medicare has selected Ozempic, Rybelsus, and Wegovy for drug price negotiation, but the negotiated Medicare price is not scheduled to begin until January 1, 2027. Here is what changed in 2026, why the timeline is confusing, and why your own costs can still vary by plan.
Osteoporosis is often treated like a women’s issue, but men can develop it too and may be diagnosed only after a serious fracture. Here is who should ask about a DXA bone density scan, how national policy differs from specialty guidance, and what Medicare may or may not cover.
The FDA has approved the first generic of Flovent HFA, but this is not a simple fix for every family affected by the brand-name inhaler’s discontinuation. Here’s what changed, who it may help, and why coverage and pharmacy access may still be uneven.
As of April 2, 2026, nothing changes at the pharmacy yet for Medicare patients taking Xeljanz, Orencia, Cosentyx, or Cimzia. What changed is that Medicare has selected these drugs for its third negotiation cycle, manufacturers are participating, and any negotiated prices would not begin until January 1, 2028.
Federal enforcement of updated hospital price transparency requirements begins April 1, 2026. That may make some hospital price listings more useful for planned care, but posted prices still are not the same as your final out-of-pocket bill.
ACA Marketplace sign-ups for 2026 came in below last year, and many households are paying more after tax credits. Here is what changed, who may still qualify to enroll, and what to do if your plan or subsidy looks wrong.
If you get Marketplace premium help in 2026, the financial stakes are higher than they were before. Extra pandemic-era subsidy boosts have ended, and for tax years after 2025 there is no repayment cap if you get too much advance premium tax credit. Here’s what that means, who should act now, and where to get help.
Many ACA Marketplace enrollees are paying more in 2026 after enhanced subsidies ended. If you already signed up, now is the time to verify premium payments, update your income information, and understand the risk of retroactive coverage loss or a tax-time payback.
CMS now requires hospitals to report clearer dollar-based pricing fields in their machine-readable files for 2026. That could make gathered pricing data easier to analyze, but it still does not give most patients an exact out-of-pocket quote.
Medicare covers some diabetes-related foot care in 2026, but not unlimited routine foot care for everyone. Here’s who qualifies for Part B foot exams and treatment every 6 months, what therapeutic shoes may be covered, what you may pay, and which symptoms should be checked sooner.
A new federal update says self-collected HPV testing should be offered as an option for average-risk women ages 30 to 65. Here’s what changed, what did not, and why many insurance plans may not have to cover the new option with no out-of-pocket costs until plan years that start in 2027.
The U.S. Preventive Services Task Force now recommends that most women start mammograms at age 40 instead of 50. Here’s what changed, what the evidence shows, and what it means for your health and insurance coverage.
Medicare has extended many telehealth flexibilities through 2026. Here’s what that means for receiving care at home, what’s covered, what you pay, and what could change next.
The latest federal survey finds mental illness remains common in the U.S., especially among teens and young adults. Millions report serious symptoms each year, and many still do not receive treatment. Here’s what the newest data show—and what it means for families, insurance coverage, and when to seek help.
New FDA-approved obesity medications have changed treatment options—but Medicare’s long-standing drug coverage rules still shape who can access them. Here’s what adults and families should understand in 2026 about eligibility, costs, and policy limits.
CMS has finalized the 2026 Medicare Physician Fee Schedule, updating how doctors are paid, refining telehealth rules, and adjusting quality programs. Here’s what those changes could mean for appointment access, costs, and care coordination.
In 2026, Medicare beneficiaries are seeing the first real-world effects of negotiated drug prices and a new $2,000 annual out-of-pocket cap under Part D. Here’s what changed, which drugs are affected, and what to check with your plan.
The March 2026 MACPAC Report to Congress reviews Medicaid and CHIP enrollment after the COVID-19 unwinding, access to care challenges, managed care oversight, and federal–state financing pressures. Here’s what families should know.
Federal rules now require hospitals and health plans to publish pricing data and cost-sharing tools. Here’s what that means for patients—and how physician practices can communicate costs clearly without overpromising.
CMS has finalized its 2026 payment rule for hospital outpatient departments and ambulatory surgery centers. Here’s what the changes mean for Medicare patients, hospital finances, and where you receive care.
A large randomized trial found that semaglutide reduced heart attacks and strokes in adults with overweight or obesity and established cardiovascular disease who did not have diabetes. Here’s what the evidence shows, what the FDA approval means, and what U.S. patients should know about safety, cost, and coverage.
OTC hearing aids are now widely available for adults with mild to moderate hearing loss. Here’s what the FDA requires, how they differ from prescription devices, what traditional Medicare does and does not cover, and when a medical exam is still essential.
End of content
End of content
